@article{3122184,
    title = "Long-term Effects of Treatment for Chronic HBV Infection on Patient-Reported Outcomes",
    author = "Younossi, Z.M. and Stepanova, M. and Younossi, I. and Pan, C.Q. and Janssen, H.L.A. and Papatheodoridis, G. and Nader, F.",
    journal = "Clinical Gastroenterology and Hepatology",
    year = "2019",
    volume = "17",
    number = "8",
    pages = "1641-1642.e1",
    publisher = "W.B. Saunders",
    issn = "1542-3565, 1542-7714",
    doi = "10.1016/j.cgh.2018.09.041",
    keywords = "adefovir;  entecavir;  lamivudine;  telbivudine;  antivirus agent;  virus DNA, adult;  antiviral therapy;  Asian;  female;  hepatitis B;  human;  major clinical study;  male;  mental health;  patient-reported outcome;  physical functioning score;  population research;  presenteeism;  productivity;  scoring system;  Short Form 36;  Short Survey;  United States;  viremia;  chronic hepatitis B;  follow up;  genetics;  Hepatitis B virus;  middle aged;  register;  retrospective study;  time factor;  virology, Antiviral Agents;  DNA, Viral;  Female;  Follow-Up Studies;  Hepatitis B virus;  Hepatitis B, Chronic;  Humans;  Male;  Middle Aged;  Patient Reported Outcome Measures;  Registries;  Retrospective Studies;  Time Factors",
    abstract = "Worldwide, viral hepatitis remains the most common cause of chronic liver disease.1 In this context, hepatitis B virus (HBV) infection and its complications are responsible for a tremendous clinical burden related to cirrhosis and hepatocellular carcinoma.1 In contrast, long-term HBV suppression can improve hepatic fibrosis and clinical outcomes.2 © 2019 AGA Institute"
}